We found that TWIST1 is overexpressed at the time of MET TKI resistance in a novel MET exon 14 mutant NSCLC patient derived xenograft (PDX) as well as in a second MET-dependent EGFR TKI acquired resistance PDX model [28, 29]. Here, TWIST1 is linked to non-small cell lung carcinoma.